Treatment with preservative-free medication can improve patient outcomes

Treatment with preservative-free medication can improve patient outcomes
evcrs_0846When it comes to medical treatment for glaucoma, available evidence demonstrates that use of a preservative-free medication has the potential to positively impact side effects, quality of life, and self-reported adherence. In addition, findings from a model simulation suggest treatment with a preservative-free medication can reduce overall costs and improve patient outcomes, said Norbert Pfeiffer MD at ESCRS Glaucoma Day 2016. Reviewing the consequences of preservative-free treatments, Dr Pfeiffer, Mainz University, Germany, noted that benzalkonium chloride (BAK) can cause side effects such as allergy and ocular surface disease that likely can reduce quality of life. He also presented findings from an open-label study in which patients experiencing adverse events while using a preservative-containing prostaglandin analogue benefited with a reduction in their signs and symptoms after switching to a preservative-free agent. The patients also reported reduced interference with their quality of life after the switch. Another study found that patients using IOP-lowering medications without preservatives had a higher self-reported medication adherence rate than their counterparts using preservative-containing medications. Analyses from a model simulating 10-year outcomes of patients being initiated on IOP-lowering treatment found that the mean total cost of treatment was higher when starting with a BAK-containing prostaglandin analogue compared with one formulated with an alternative, gentler preservative. The model also predicted differences favouring use of the latter medication regarding proportions of patients remaining on their first- or second-line treatment, needing laser or surgical intervention, and progressing to more advanced disease.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...